EMEA-001030-PIP01-10-M07

Key facts

Invented name
Invokana
Active substance
canagliflozin
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0205/2017
PIP number
EMEA-001030-PIP01-10-M07
Pharmaceutical form(s)
Tablet
Condition(s) / indication(s)
Treatment of type-2 diabetes mellitus
Route(s) of administration
Oral use
Contact for public enquiries
Janssen-Cilag International N.V.
France
Tel.+33 55004066
E-mail: ihammer@its.jnj.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating